AR106301A1 - Composiciones de pirrolpirimidina como inhibidores de quinasas - Google Patents

Composiciones de pirrolpirimidina como inhibidores de quinasas

Info

Publication number
AR106301A1
AR106301A1 ARP160103082A ARP160103082A AR106301A1 AR 106301 A1 AR106301 A1 AR 106301A1 AR P160103082 A ARP160103082 A AR P160103082A AR P160103082 A ARP160103082 A AR P160103082A AR 106301 A1 AR106301 A1 AR 106301A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
substituted
halo
hydroxyl
Prior art date
Application number
ARP160103082A
Other languages
English (en)
Spanish (es)
Inventor
Wang Xiaobo
Xu Wanhong
Xu Xiao
Wu Jian
Mo Xiaopeng
Weng Bojie
Bao Yimei
Dai Kongen
Hua Yuning
Chen Yile
Liu Jia
Mao Long
Original Assignee
Acea Biosciences Inc
Acea Bio Hangzhou Co Ltd
Acea Pharmaceutical Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acea Biosciences Inc, Acea Bio Hangzhou Co Ltd, Acea Pharmaceutical Res Co Ltd filed Critical Acea Biosciences Inc
Publication of AR106301A1 publication Critical patent/AR106301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP160103082A 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas AR106301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015091536 2015-10-09

Publications (1)

Publication Number Publication Date
AR106301A1 true AR106301A1 (es) 2018-01-03

Family

ID=58487279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103082A AR106301A1 (es) 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas

Country Status (13)

Country Link
US (1) US10533011B2 (enExample)
EP (1) EP3359159B1 (enExample)
JP (1) JP6889494B2 (enExample)
KR (1) KR20180067584A (enExample)
CN (1) CN107949388B (enExample)
AR (1) AR106301A1 (enExample)
AU (1) AU2016334141B2 (enExample)
BR (1) BR112018006939A2 (enExample)
CA (1) CA3001744C (enExample)
MX (1) MX2018004332A (enExample)
RU (1) RU2018115334A (enExample)
TW (1) TW201722431A (enExample)
WO (1) WO2017059702A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
CN104203924B (zh) * 2012-01-13 2019-06-11 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
KR102173433B1 (ko) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
AU2016334141B2 (en) 2015-10-09 2019-12-19 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
AU2017408099A1 (en) * 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
EP3833659A4 (en) * 2018-08-09 2022-03-30 ACEA Therapeutics, Inc. METHOD FOR MAKING (S)-N-(3-((2- ((4-((1-ACETYLPYRROLIDIN-3-YL)(METHYL)AMINO)PHENYL)AMINO)-5-METHOXYRIMIDIN-4-YL)OXY ) PHENYL)ACRYLAMIDE, AND RELATED FORMULATIONS
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024092047A1 (en) 2022-10-26 2024-05-02 Sorrento Therapeutics, Inc. Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
CN120737091B (zh) * 2025-08-29 2025-11-04 四川大学华西医院 一种以7-脱氮鸟嘌呤为骨架的化合物、药物组合物及用途

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974277A (en) 1974-09-06 1976-08-10 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
KR100861486B1 (ko) 2001-02-21 2008-10-02 미쓰비시 타나베 파마 코퍼레이션 퀴나졸린 유도체
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
WO2005047482A2 (en) 2003-11-12 2005-05-26 Xiao Xu Real time electronic cell sensing systems and applications for cell-based assays
CN100577811C (zh) 2002-07-20 2010-01-06 美国艾森生物科学公司 基于阻抗分析细胞和颗粒的装置和方法
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
WO2004045624A1 (ja) 2002-11-15 2004-06-03 Mitsubishi Pharma Corporation 医薬製剤組成物
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
WO2005065156A2 (en) 2003-12-23 2005-07-21 First Data Corporation Global positioning system
CN1997644A (zh) 2004-03-02 2007-07-11 神经能质公司 被芳基取代的嘌呤类似物
AU2005265017A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
AU2006298882B2 (en) 2005-09-21 2011-10-27 4Sc Ag Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles
TW200800215A (en) 2005-10-13 2008-01-01 Glaxo Group Ltd Novel compounds
KR100832593B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2644494A1 (en) 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
CA2647543A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2008039359A2 (en) 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
PL2091918T3 (pl) 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
EP2124954A2 (en) 2007-01-26 2009-12-02 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
PT2114900T (pt) 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009020990A1 (en) 2007-08-08 2009-02-12 Smithkline Beecham Corporation 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
AU2008314632B2 (en) 2007-10-19 2015-05-28 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA3031835C (en) 2008-06-27 2021-09-07 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2010045451A1 (en) 2008-10-16 2010-04-22 Glaxosmithkline Llc Pyrrolopyrimidine compounds
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
PT2975042T (pt) 2010-06-23 2019-01-11 Hanmi Science Co Ltd Novos derivados de pirimidina fundidos para inibição de atividade de tirosina-quinase
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2644151C2 (ru) 2010-11-01 2018-02-08 Селджен Авиломикс Рисерч, Инк. Гетероциклические соединения и их применение
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
CN102583089B (zh) 2011-01-11 2015-11-25 山东新北洋信息技术股份有限公司 薄片类介质处理装置
JP2014511391A (ja) 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN104203924B (zh) * 2012-01-13 2019-06-11 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) * 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
RS58043B1 (sr) * 2012-04-24 2019-02-28 Vertex Pharma Inhibitori dna-pk
EP3170825B1 (en) 2012-08-06 2019-04-10 ACEA Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
KR102173433B1 (ko) * 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
CN104306348B (zh) 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN105185339B (zh) 2015-10-08 2017-12-29 京东方科技集团股份有限公司 移位寄存器单元、栅线驱动装置以及驱动方法
AU2016334141B2 (en) 2015-10-09 2019-12-19 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
ES2912648T3 (es) 2015-11-16 2022-05-26 Topadur Pharma Ag Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f] [1,2,4]triazinona como inhibidores de la fosfodiesterasa y usos de los mismos
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same

Also Published As

Publication number Publication date
MX2018004332A (es) 2019-01-10
AU2016334141A1 (en) 2018-04-26
EP3359159B1 (en) 2023-06-07
US20180312510A1 (en) 2018-11-01
CN107949388B (zh) 2021-10-26
CN107949388A (zh) 2018-04-20
EP3359159A4 (en) 2019-06-05
CA3001744A1 (en) 2017-04-13
CA3001744C (en) 2024-09-27
BR112018006939A2 (en) 2018-10-16
KR20180067584A (ko) 2018-06-20
TW201722431A (zh) 2017-07-01
AU2016334141B2 (en) 2019-12-19
RU2018115334A3 (enExample) 2019-11-29
US10533011B2 (en) 2020-01-14
JP2018530610A (ja) 2018-10-18
JP6889494B2 (ja) 2021-06-18
EP3359159A1 (en) 2018-08-15
WO2017059702A1 (en) 2017-04-13
HK1253537A1 (en) 2019-06-21
RU2018115334A (ru) 2019-11-11

Similar Documents

Publication Publication Date Title
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR110922A1 (es) Compuestos inhibidores del vih
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR088449A1 (es) Benzilindazoles sustituidos
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR092742A1 (es) Piridinonas antifibroticas
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR091185A1 (es) Derivados de 1,2,4-triazol
AR097866A1 (es) Derivados de 4-azaindol
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR098492A1 (es) Derivados de purina
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure